Pharmacologic problems in shock research.
Recent advances with receptor-selective agonists and antagonists have provided great impetus to the deployment of drugs as experimental tools in cardiovascular research. Often overlooked, however, is the important limitation that few exogenous chemicals actually exert only one biologic action. This discussion appraised several prototype drugs used in this field, and theorized how a lack of consideration of subsidiary pharmacologic actions may lead to over-simplified interpretations of drug-based data.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000617:Aminoglycosides / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D004195:Disease Models, Animal; D004285:Dogs; D007213:Indomethacin / Q000494:pharmacology; D012769:Shock / Q000188:drug therapy* / Q000209:etiology
D000317:Adrenergic alpha-Antagonists; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D016861:Cyclooxygenase Inhibitors; D001241:Aspirin; D007213:Indomethacin